{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T03:22:04Z","timestamp":1777432924268,"version":"3.51.4"},"reference-count":22,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T00:00:00Z","timestamp":1550102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Australas Psychiatry"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To describe prescription of sodium valproate (SV) for bipolar mood disorder to potentially child-bearing women within one public mental health service and describe risks of fetal exposure, and safe prescribing practices among psychiatrists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A 24-month retrospective chart review with descriptive analysis; narrative review of literature and guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Review of 383 charts demonstrated prescription of valproate to 20% of 98 women aged 15\u201345, with little evidence of advice regarding risk and contraception. Robust evidence of teratogenic and neurodevelopmental risk underpins increased regulation, and recommendations that valproate not be prescribed to this cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The significant risks associated with SV oblige all prescribers to proactively access authoritative guidelines such as those published by the Centre of Perinatal Excellence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1039856219828175","type":"journal-article","created":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T13:01:40Z","timestamp":1550149300000},"page":"125-128","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["\u2018Conceivably Neglected\u2019 \u2013 Are prescribers sufficiently aware of the risks of prescribing sodium valproate to women with mental illness?"],"prefix":"10.1177","volume":"27","author":[{"given":"Charana","family":"Perera","sequence":"first","affiliation":[{"name":"Advanced trainee, Royal Australian and New Zealand College of Psychiatrists, Redcliffe-Caboolture Mental Health Service, Metro-North Mental Health Service, Brisbane, QLD, and; University of Queensland, Brisbane, QLD, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue","family":"Patterson","sequence":"additional","affiliation":[{"name":"Principal Research Fellow, Metro-North Mental Health Service, Brisbane, QLD, and; University of Queensland, Brisbane, QLD, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6961-0902","authenticated-orcid":false,"given":"George","family":"Bruxner","sequence":"additional","affiliation":[{"name":"Consultant Psychiatrist and staff specialist, Fellow Royal Australian and New Zealand College of Psychiatrists, Redcliffe-Caboolture Mental Health Service, Metro-North Mental Health Service, Brisbane, QLD, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,2,14]]},"reference":[{"key":"bibr1-1039856219828175","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2011.12"},{"key":"bibr2-1039856219828175","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(15)30147-4"},{"key":"bibr3-1039856219828175","doi-asserted-by":"publisher","DOI":"10.1177\/0004867415617657"},{"key":"bibr4-1039856219828175","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852913000990"},{"key":"bibr5-1039856219828175","unstructured":"European Medicine Agency. New measures to avoid valproate exposure in pregnancy, https:\/\/www.ema.europa.eu\/en\/news\/new-measures-avoid-valproate-exposure-pregnancy-endorsed (2018, accessed 14 November 2018)"},{"key":"bibr6-1039856219828175","unstructured":"National Institute for Health and Care Excellence. Antenatal and postnatal mental health: clinical management and service guidance. Clinical guideline [CG192], https:\/\/www.nice.org.uk\/guidance\/cg192 (2018, accessed 14 November 2018)."},{"key":"bibr7-1039856219828175","unstructured":"Medicines and Healthcare products Regulatory Agency. Valproate use by women and girls, https:\/\/www.gov.uk\/guidance\/valproate-use-by-women-and-girls#toolkit (2018, accessed 14 November 2018)."},{"key":"bibr8-1039856219828175","doi-asserted-by":"publisher","DOI":"10.1111\/j.1479-828X.2011.01359.x"},{"key":"bibr9-1039856219828175","unstructured":"Centre of Perinatal Excellence. 2017 National Perinatal Mental Health Guideline, http:\/\/cope.org.au\/about\/review-of-new-perinatal-mental-health-guidelines\/ (2017, accessed 14 November 2018)."},{"key":"bibr10-1039856219828175","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1984.tb05641.x"},{"key":"bibr11-1039856219828175","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.158"},{"key":"bibr12-1039856219828175","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30107-8"},{"key":"bibr13-1039856219828175","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70323-X"},{"key":"bibr14-1039856219828175","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.2270"},{"key":"bibr15-1039856219828175","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001772"},{"key":"bibr16-1039856219828175","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.3897"},{"key":"bibr17-1039856219828175","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2015.02.030"},{"key":"bibr18-1039856219828175","unstructured":"Food and Drug Administration. FDA Drug Safety Communication: valproate anti-seizure products contraindicated for migraine prevention in pregnant women due to decreased IQ scores in exposed children, https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm350684.htm (2013, accessed 14 November 2018)."},{"key":"bibr19-1039856219828175","volume":"358","author":"Wise J","year":"2017","journal-title":"BMJ"},{"key":"bibr20-1039856219828175","first-page":"890","volume":"45","author":"Boyce P","year":"2016","journal-title":"Aust Fam Physician"},{"key":"bibr21-1039856219828175","doi-asserted-by":"publisher","DOI":"10.1007\/s00737-009-0060-y"},{"key":"bibr22-1039856219828175","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2015.02.033"}],"container-title":["Australasian Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1039856219828175","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1039856219828175","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1039856219828175","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:49:59Z","timestamp":1777376999000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1039856219828175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,14]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1177\/1039856219828175"],"URL":"https:\/\/doi.org\/10.1177\/1039856219828175","relation":{},"ISSN":["1039-8562","1440-1665"],"issn-type":[{"value":"1039-8562","type":"print"},{"value":"1440-1665","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,14]]}}}